Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Terminated

Phase 2 Results N/A

Summary of Purpose

The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset. Trial Stopped: CO Phase 2 data did not show sufficient improvement in cath opening at higher dose/concentration evaluated. Nuvelo ended further clinical dev of alfimeprase.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 22 April 2008.

1 Jun 2007 10 Jul 2007 1 May 2008 1 May 2008 1 Apr 2008 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment

Contacts

  • Christine Choy 650-517-8492 2nd contact: Susan M Begelman, MD 650-517-8470 sbegelman@nuvelo.com

    cchoy@nuvelo.com